Sarah Arbe‐Barnes

Identification of an antimalarial synthetic trioxolane drug development candidate

Jonathan L. Vennerstrom, Sarah Arbe‐Barnes, Reto Brun et al. · Nature · 2004 · 617 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

Susan A. Charman, Sarah Arbe‐Barnes, Ian Bathurst et al. · Proceedings of the National Academy of Sciences · 2011 · 376 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Stroke Treatment Academic Industry Roundtable X

Sean I. Savitz, Jean‐Claude Baron, Marc Fisher et al. · Stroke · 2019 · 192 citations

Medicine, Health Policy, Neurology +10

Review of pyronaridine anti-malarial properties and product characteristics

Simon L. Croft, Stephan Duparc, Sarah Arbe‐Barnes et al. · Malaria Journal · 2012 · 158 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

First‐in‐man safety and pharmacokinetics of synthetic ozonide <scp>OZ439</scp> demonstrates an improved exposure profile relative to other peroxide antimalarials

Joerg J. Moehrle, Stephan Duparc, Christoph Siethoff et al. · British Journal of Clinical Pharmacology · 2012 · 116 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8